Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer: 2.5-year follow-up.
Hasenburg, A
Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer: 2.5-year follow-up. [electronic resource] - Gynecologic oncology Dec 2001 - 549-54 p. digital
Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
0090-8258
10.1006/gyno.2001.6442 doi
Acyclovir--pharmacokinetics
Adenoviridae--enzymology
Adult
Aged
Antineoplastic Agents--pharmacokinetics
Antiviral Agents--pharmacokinetics
Combined Modality Therapy
Enzyme Inhibitors--pharmacokinetics
Female
Genetic Therapy--methods
Humans
Middle Aged
Ovarian Neoplasms--drug therapy
Second-Look Surgery
Thymidine Kinase--genetics
Topotecan--pharmacokinetics
Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer: 2.5-year follow-up. [electronic resource] - Gynecologic oncology Dec 2001 - 549-54 p. digital
Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
0090-8258
10.1006/gyno.2001.6442 doi
Acyclovir--pharmacokinetics
Adenoviridae--enzymology
Adult
Aged
Antineoplastic Agents--pharmacokinetics
Antiviral Agents--pharmacokinetics
Combined Modality Therapy
Enzyme Inhibitors--pharmacokinetics
Female
Genetic Therapy--methods
Humans
Middle Aged
Ovarian Neoplasms--drug therapy
Second-Look Surgery
Thymidine Kinase--genetics
Topotecan--pharmacokinetics